Background: Nesfatin-1 is a novel anorectic neuropeptide with potent metabolic regulatory effects. Aim: We aimed to evaluate the relationship between nesfatin-1 levels and slow coronary flow (SCF). Methods: A total of 60 consecutive patients with SCF and 60 consecutive patients with normal coronary flow (NCF) were enrolled into the study. Nesfatin-1 level was measured from blood serum samples using enzyme-linked immunosorbent assay test. Results: Serum nesfatin-1 levels were significantly lower in the SCF group compared to the NCF group (p < 0.001). Low levels of nesfatin-1 were found to be significantly and independently associated with the SCF (odds ratio 0.982, 95% confidence interval 0.969-0.995, p = 0.005). Conclusions: The results of this study showed that serum nesfatin-1 level was lower in the SCF group than in the NCF group. Nesfatin-1 could play a role in the pathogenesis of SCF phenomenon with mechanisms such as inflammation and endothelial dysfunction. Further studies are needed to determine the relation between SCF and nesfatin-1.
CITATION STYLE
Kuyumcu, M. S., Kuyumcu, A., Yayla, Ç., Özbay, M. B., Alagöz, M., Ünal, S., … Samur, G. (2018). Nesfatin-1 levels in patients with slow coronary flow. Kardiologia Polska, 76(2), 401–405. https://doi.org/10.5603/KP.a2017.0210
Mendeley helps you to discover research relevant for your work.